How Today's Developments in the Treatment of Non-Small Cell Lung Cancer Will Change Tomorrow's Standards of Care

How Today's Developments in the Treatment of Non-Small Cell Lung Cancer Will Change Tomorrow's Standards of Care Mark G. Kris Oncologist 2005; 10: 23-29 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lung cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the current status of adjuvant therapy in NSCLC. Articulate the developing role of targeted agents in the treatment of NSCLC. Describe how tumor molecular biology may impact response to novel treatment. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 04, 2005 Most Recent Review: Nov. 04, 2005* Most Recent Update: Nov. 04, 2005 Date Credit Expires: Nov. 04, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.